Eight years after legalization, Canadians seeking CBD for health reasons are stuck in a system that doesn’t serve them. Licensed retailers reward high‑THC products, while medical oversight has thinned, leaving patients navigating a cumbersome, fragmented pathway.
Access Gap Threatens Health‑Focused Users
A review of Ontario’s catalogue found only 1.2% of listings were THC‑free, and about 80% of new products disappear within a year. Medical registrations fell 57% from 2020 to 2025, and practitioner numbers dropped by more than half. The result is an access gap that forces users to search online for unregulated options.
Regulatory Shortfall
Health Canada once promised a prescription‑free pathway for CBD health products, but the 2025–2027 Forward Regulatory Plan removed that option. The medical system, the only consistent route, struggles with low patient numbers and fewer clinicians.
Industry Response
Kinloch.med, an online platform launched by CEO Ed Collins of Kinloch Brands Ltd., bundles clinical intake, nurse‑practitioner review, medical authorization and product delivery into a single streamlined process. The aim is to preserve oversight while cutting the bureaucratic friction that stalled one user’s six‑week authorization for stage‑3 colon cancer treatment.
For patients like the author’s mother, a six‑week wait is unacceptable; they need rapid, reliable access. Until a clearer regulatory path emerges, the current framework must evolve to meet diverse consumer needs.
